Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Mol Med (Berl). 2012 Nov 22;91(5):549–559. doi: 10.1007/s00109-012-0983-z

Table 1.

Drugs with efficacy in human with renal diseases and fibrosis.

Drug class/Drug Human renal diseases Outcomes studied in human trials Experimental Models of Renal fibrosis
Tranilast DKD [65, 66] UACR, GFR decline, Urinary Type IV Collagen excretion Sub-total nephrectomy [69]
Pyridone: Pirfenidone and fluorofenidone FSGS [67], DKD [73] UACR, GFR decline, Urinary TGF-β excretion UUO [71], Subtotal Nephrectomy [72]
Renin-Angiotensin-Aldosterone system blockade Diabetic, Non-diabetic, and Glomerular kidney diseases [74–78] UACR, GFR decline Subtotal Nephrectomy [135, 136]
Anti-CTGF monoclonal antibody (FG-3019) DKD [98] UACR UUO [96, 97], DKD[95]

DKD: Diabetic kidney disease, FSGS: focal segmental glomerular sclerosis, CKD: chronic kidney disease, IgAN: IgA nephropathy, GFR: glomerular filtration rate, UUO: unilateral ureteral obstruction, UACR: urinary albumin to creatinine ratio.